drugset / Trial / NCT07648225
UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)
RandomizedParallel-groupTriple-blindTreatment
Summary
This randomized, double-blind, parallel, placebo-controlled phase Ⅲ study to evaluate the efficacy and safety of UBT251 Injection in overweight/obese patients
Timeline
- Start
- 2026-07-31
- Primary completion
- 2027-09-29
- Completion
- 2027-11-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UBT251 | Unknown | 4 mg | Subcutaneous |
| Subject | UBT251 | Unknown | 6 mg | Subcutaneous |